In the study, the anti-inflammatory impacts of Mu Dan Pi and its primary active compounds on inflammatory bowel disease were assessed systematically. Screening was done via NF-κB and interferon regulatory factor reporter assays in THP-1 cells, stimulated with particular gene activators. This process was later verified in bone marrow-derived macrophages. The water extract of Mu Dan Pi considerably hindered the activation of NF-κB and IRF reporters, modifying downstream signaling pathways and decreasing the production of IL-6 and TNF-α, based on dosage.

In subsequent observations, among the five known active components identified within Mu Dan Pi, one component known as PGG distinguished itself as the most effective at inhibiting reporters and reducing IL-6 and TNF-α. On a clinical application level, both MDP powder and its water extract mitigated colitis and pathological changes in mice, although PGG did not present any significant reduction. This suggests that the anti-inflammatory qualities of Mu Dan Pi may hold therapeutic potential for inflammatory bowel disease.